Business Context and Reporting Period
This Form 8-K reports on the results of the 2016 Annual Meeting of Stockholders held by Capricor Therapeutics, Inc. on June 2, 2016. The meeting took place at the company's principal executive offices in Beverly Hills, California.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 15,339,487 of 17,952,323 outstanding shares voted on three proposals. All proposals were approved:
- Board Election: Seven directors were elected to serve until the 2017 annual meeting. The slate originally included eight nominees, but Mr. Lou Grasmick was withdrawn following his death on May 26, 2016. The elected directors are Frank Litvack, M.D., Linda Marbán, Ph.D., David B. Musket, George W. Dunbar, Jr., Louis Manzo, Earl M. (Duke) Collier, Jr., and Joshua Kazam.
- Equity Plan Amendment: Stockholders approved amendments to the 2012 Restated Equity Incentive Plan. The number of shares available for issuance was increased to 4,149,710 plus 2% of outstanding shares as of December 31, 2015. The plan includes an automatic annual increase of 2% of outstanding shares commencing January 1, 2017.
- Auditor Ratification: The appointment of Rose, Snyder & Jacobs LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016, was ratified.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves strictly as a disclosure of the voting outcomes.
Investor Verification Checklist
- Verify the updated composition of the Board of Directors following the withdrawal of Mr. Grasmick.
- Review the definitive proxy statement filed on April 28, 2016, for detailed terms of the 2012 Equity Incentive Plan amendments.
- Confirm the engagement of Rose, Snyder & Jacobs LLP for the 2016 fiscal year audit.
- Note the high level of broker non-votes (3,311,223 shares) on director elections and the equity plan amendment, which did not affect the outcome but indicates broker discretion on those specific items.